CTIS2023-508791-11-00招募中1 期
A placebo-controlled, double-blinded, randomized, dose-finding trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
Akl Research & Development Limited0 个研究点目标入组 225 人开始时间: 2024年1月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •The participant is able to read and understand the language and content of the study material, understand and comply with the requirements of the study, and is willing to provide information at the scheduled evaluations and appropriate written informed consent has been obtained., Age between 40 years and 85 years at the time of screening (inclusive) of either sex., Femorotibial osteoarthritis of the knee, according to the American College of Rheumatology (ACR) clinical and radiographic criteria (Appendix I)., Radiological OA grade 2 or 3 of the target knee, using the Kellgren-Lawrence method (Kellgren & Lawrence 1957) as graded by central, independent reading of a Fixed-Flexion X-ray obtained during screening, or on a recent (within 6 months) X-ray image which fulfills the protocol specifications for reading., Screening and baseline target knee WOMAC pain sub-score (5 questions) = 25 and < 45 out of 50., PainDETECT = 13out of 38 at screening, Failure in response or intolerance of at least one OA therapy (e.g. physiotherapy, paracetamol, local or systemic NSAID, short term opioid use, injections of hyaluronic acid, or corticosteroids) in the opinion of the investigator.
排除标准
- •Known or suspected hypersensitivity to or previous hypersensitivity reactions to APPA, or any of the excipients in the investigational product., Current malignancy or treatment for malignancy within the past five years, apart from resected basal cell carcinoma, squamous skin cell carcinoma, or resected cervical atypia or carcinoma in situ, unless affecting the target knee area., Any other abnormal laboratory results or significant medical conditions that the Investigator believes should preclude participation in the trial., Prior septic arthritis of the target knee., Known OA of the hip(s) if pain in either or both hip(s) exceeds that of the target knee on the WOMAC Hip Pain sub-score at the time of screening., Active comorbid condition other than OA (e.g radicular back pain, bursitis, tendinitis) significantly affecting target knee pain reporting in the opinion of the investigator., Body Mass Index = 40 kg/m2, Estimated glomerular filtration rate < 30 mL/min using the Modification of Diet in Renal Disease (MDRD) method., Substantial use of moderate or higher strength opioid medication within 6 weeks before the screening visit, as evaluated by the investigator., Use of serotonin–norepinephrine reuptake inhibitors (i.e duloxetine), pregabalin, or gabapentin within 4 weeks before the screening visit., History of alcohol or drug abuse within the 5 years prior to randomization, in the opinion of the investigator., For women of childbearing potential: a. Pregnancy (i.e. positive serum pregnancy test at screening) or breastfeeding b. Failure to agree to practice a highly effective method of contraception (see Appendix II), from enrolment up to at least 3 months after the study end., For sexually active men with a female partner of childbearing potential: a. Failure to agree to ensure that their female partners use a highly effective method of contraception (see Appendix II) from enrolment up to at least 3 months after the study end. b. Failure to agree not to donate sperm throughout the study and at least 3 months after the study end., Intra-articular injection of corticosteroids within 3 months or hyaluronic acid within 6 months of screening in the target knee or into any other major joint within 30 days prior to screening (for extended-release corticosteroid injections: within 6 months in target knee and 3 months into any other major joint)., Systemic corticosteroid treatment for the treatment of musculoskeletal conditions of more than 14 days during the past 6 months prior to screening., Target knee major surgery or arthroscopy within the year prior to screening., Planned surgery on either knee within the next 6 months., Use of a currently unapproved investigational drug, device, or biologic within 3 months prior to randomization., Presence of inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, polymyalgia rheumatica, gout or pseudogout with significant history of clinical attacks (in the opinion of the investigator), or presence of connective tissue disease.
研究者
相似试验
进行中（未招募）
1 期
A placebo-controlled, double-blinded, randomized, trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritisRadiographic and symptomatic knee osteoarthritis in either one or both kneesMedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2020-000249-14-DKAKL Research and Development Ltd150
已完成
Unknown
An efficacy study of a topical cream, ar-Turmerone on female subjects with hirsutism.CTRI/2023/04/052032Sami-Sabinsa Group Ltd.33
招募中
1 期
‘A clinical trial to test the safety and immune responses from the BG505 SOSIP.664 gp140 HIV vaccine in development’.PACTR202006565880683IAVI60
尚未招募
不适用
A randomized, double-blinded, placebo-controlled, crossover study of 5-aminolevulinic acid in the prevention of migraineMigraineJPRN-UMIN000019084Department of neurosurgery, Osaka Medical college50
已完成
不适用
A randomized, double-blinded, placebo-controlled, single centre, phase I study of the safety of escalating single intravenous doses of NI-0801 in healthy volunteers.psoriasis10003816NL-OMON33532ovImmune S.A.30